抗生素开发商smartbax扩大融资，用于开发靶向多重耐药病原体的候选药物-动脉网

smartbax Expands Funding Round for Drug Candidate Targeting Multidrug-Resistant Pathogens

D-Pharm 等信源发布 2026-07-02 13:36



可切换为仅中文







smartbax, a biotech company developing next-generation

smartbax，一家开发下一代技术的生物科技公司

antibiotics

抗生素

, announced the successful second closing of its Pre-Series A funding round. With the additional investment from a single-family office based in Frankfurt, the total volume of the funding round has increased to 6.3 million euros. In addition to this new investment, smartbax is supported by a strong consortium of investors comprising Anobis Asset, Bayern Kapital, the Boehringer Ingelheim Venture Fund (BIVF), HTGF – High-Tech Gründerfonds, and UnternehmerTUM Funding for Innovators..

，宣布其Pre-A轮融资第二轮关闭圆满成功。随着一家总部位于法兰克福的家族办公室追加投资，该轮融资总额已增至630万欧元。除了这笔新投资外，smartbax还得到了一个强大的投资者联盟的支持，其中包括Anobis Asset、Bayern Kapital、勃林格殷格翰风险投资基金（BIVF）、HTGF（高科技创业基金）以及UnternehmerTUM创新者基金。

With the additional funds, smartbax will further develop its flagship antibacterial program, which was recently in-licensed from Aicuris, through to the IND submission. The low-molecular-weight active ingredient targets a step in the biosynthesis of lipopolysaccharides (LPS)—an essential structural component of the outer membrane of Gram-negative bacteria—that has not yet been exploited in antibiotic development.

凭借新增资金，smartbax 将进一步推进其从 Aicuris 近期许可引进的旗舰抗菌项目，直至提交新药临床试验申请（IND）。该低分子量活性成分靶向脂多糖（LPS）生物合成中的一个步骤；脂多糖是革兰氏阴性菌外膜的关键结构成分，而这一靶点在抗生素开发中尚未被利用。

The program has already demonstrated its efficacy .

该计划已证明其有效性。

in vivo

体内

, including against multidrug-resistant pathogens, and shows potential for oral administration.

，包括对多重耐药病原体有效，并显示出口服给药的潜力。

At the same time, smartbax is continuing to advance the development of its proprietary pipeline of small-molecule antibiotics. This includes two activators of bacterial hydrolases that trigger the self-digestion of bacteria via a novel mechanism of action. The programs target both Gram-positive and Gram-negative pathogens and have so far demonstrated promising drug properties, activity against biofilms, and no observed development of resistance..

与此同时，smartbax 正在持续推进其专有小分子抗生素产品线的开发。其中包括两种细菌水解酶激活剂，它们通过一种新颖的作用机制触发细菌的自我消化。这些项目针对革兰氏阳性和革兰氏阴性病原体，迄今已展现出良好的药物特性、对生物膜的活性，且未观察到耐药性的产生。

Dr. Robert Macsics, CEO of smartbax, said: “With this additional investment, we can advance our lead program to the IND filing stage, thereby taking an important step in the further development of our pipeline. At the same time, we are continuing to invest in our proprietary enzymatic activators, which take a fundamentally different approach to combating bacterial infections.

smartbax 首席执行官 Robert Macsics 博士表示：“通过这笔额外投资，我们可以将我们的领先项目推进至新药临床试验申请（IND）提交阶段，从而在进一步开发我们的产品线方面迈出重要一步。同时，我们继续投资于我们专有的酶激活剂，其采用从根本上不同的方法来对抗细菌感染。”

Together, these programs support our goal of addressing the growing challenge of antimicrobial resistance.”.

这些项目共同支持我们应对日益严峻的抗菌药物耐药性挑战的目标。

Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar.

注意：本文已由计算机系统自动翻译，未经人工干预。LUMITOS 提供这些自动翻译，旨在呈现更广泛的最新新闻。由于本文系自动翻译，因此在词汇、句法或语法方面可能存在错误。

The original article in German can be found .

德文原文可在以下位置找到。

here

这里

。

https://www.bionity.com/en/news/1189094/smartbax-expands-funding-round-for-drug-candidate-targeting-multidrug-resistant-pathogens.html

Novel antibiotics in the fight against antimicrobial resistance

抗击抗菌素耐药性的新型抗生素

SANTERO announces a €8 million Series A funding round led by Newton Biocapital

SANTERO宣布完成由Newton Biocapital领投的800万欧元A轮融资

Read news